
Carbapenemase-producing enterobacteria (CPE) spread all over the world during the last years, causing serious infections with increasing frequency. Very few new drugs active against CPE are expected to be clinically available. Studies summarized in this review show that there is yet room to improve our therapeutic approaches, in the treatment of infections due to CPE.
Bacterial Proteins, Enterobacteriaceae, Drug Design, Enterobacteriaceae Infections, Humans, Microbial Sensitivity Tests, beta-Lactamases, Anti-Bacterial Agents
Bacterial Proteins, Enterobacteriaceae, Drug Design, Enterobacteriaceae Infections, Humans, Microbial Sensitivity Tests, beta-Lactamases, Anti-Bacterial Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
